Vantia Therapeutics ^Private

Vantia Therapeutics is an emerging pharmaceutical company focused on developing small molecule drugs to address unmet medical needs. With a strong clinical pipeline, their drug candidates target conditions such as nocturia and dysmenorrhoea, which affect millions of people and have limited treatment options. Vantia's strategy involves advancing their proprietary drugs through Phase II clinical testing and then partnering with other companies for commercialization. Founded in 2008, Vantia Therapeutics is supported by leading life science investors Novo A/S, SV Life Sciences, and MVM Life Science Partners.